NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis

BACKGROUND: Cortical lesions (CLs) are typical of multiple sclerosis (MS) and have been recently incorporated in MS diagnostic criteria. Thus, the ‘no evidence of disease activity’ (NEDA) definition should now include CLs. The aim of this study was to evaluate the NEDA3 + CL status in natalizumab- o...

Descripción completa

Detalles Bibliográficos
Autores principales: Puthenparampil, Marco, Cazzola, Chiara, Zywicki, Sofia, Federle, Lisa, Stropparo, Erica, Anglani, Mariagiulia, Rinaldi, Francesca, Perini, Paola, Gallo, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204617/
https://www.ncbi.nlm.nih.gov/pubmed/30386435
http://dx.doi.org/10.1177/1756286418805713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204617/
https://www.ncbi.nlm.nih.gov/pubmed/30386435
http://dx.doi.org/10.1177/1756286418805713

Ejemplares similares